Drug disposition during development
Morselli, P.L.
Acta Pharmaceutica Suecica 11(6): 647
1974
ISSN/ISBN: 0001-6675 PMID: 1136799 Document Number: 80234
Document emailed within 1 workday
Related Documents
Vaden, S.L.; Page, R.L.; Peters, B.P.; Cline, J.M.; Riviere, J.E. 1993: Development and characterization of an isolated and perfused tumor and skin preparation for evaluation of drug disposition Cancer Research 53(1): 101-105Maftouh, M.; Monsarrat, B.; Rao, R.C.; Meunier, B.; Paoletti, C. 1984: Identification of the glucuronide and glutathione conjugates of the antitumor drug N2-methyl-9-hydroxyellipticinium acetate (Celiptium). Comparative disposition of this drug with its olivacinium isomer in rat bile Drug Metabolism and Disposition: the Biological Fate of Chemicals 12(1): 111-119
1982: Drug disposition in old age New England Journal of Medicine 307(17): 1087-1089
Hogan, L. 1982: Drug disposition in the elderly Journal of the Kansas Medical Society 83(7): 380
Yerby, M.S.; Friel, P.N.; McCormick, K. 1992: Antiepileptic drug disposition during pregnancy Neurology 42(4 Suppl 5: 12-16
Yaffe, S.J. 1973: Drug disposition in the fetus and newborn infant Rhode Island Medical Journal 56(7): 280-285 Passim
Stewart, C.F.; Hampton, E.M. 1987: Effect of maturation on drug disposition in pediatric patients Clinical Pharmacy 6(7): 548-564
Riska, P.; Lamson, M.; MacGregor, T.; Sabo, J.; Hattox, S.; Pav, J.; Keirns, J. 1999: Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug Metabolism and Disposition: the Biological Fate of Chemicals 27(8): 895-901
Whitehouse, P.J.; Sciulli, C.G.; Mason, R.M. 1997: Dementia drug development: use of information systems to harmonize global drug development Psychopharmacology Bulletin 33(1): 129-133
Wu, X.-m.; Sheng, L.; Jia, Y.-f.; Li, Y. 2016: Role of breast cancer resistance protein in drug disposition Yao Xue Xue Bao 51(9): 1368-1377
Kalir, B. 2005: The Development of a Migratory Disposition: Explaining a "New Emigration" International Migration 43(4): 167-196
Verbeeck, R.K. 1982: Glucuronidation and disposition of drug glucuronides in patients with renal failure. a review Drug Metabolism and Disposition: the Biological Fate of Chemicals 10(1): 87-89
Pochapsky, S.S.; Pochapsky, T.C. 2001: Nuclear magnetic resonance as a tool in drug discovery, metabolism and disposition Current Topics in Medicinal Chemistry 1(5): 427-441
Dorr, R.T.; Alberts, D.S. 1985: Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse Journal of the National Cancer Institute 74(1): 113-120
Kawai, K.; Kawasaki-Tokui, Y.; Odaka, T.; Tsuruta, F.; Kazui, M.; Iwabuchi, H.; Nakamura, T.; Kinoshita, T.; Ikeda, T.; Yoshioka, T.; Komai, T.; Nakamura, K. 1997: Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs Arzneimittel-Forschung 47(4): 356-368
Manning, B.W.; Franklin, M.R.; Galinsky, R.E. 1991: Drug metabolizing enzyme changes after chronic buthionine sulfoximine exposure modify acetaminophen disposition in rats Drug Metabolism and Disposition: the Biological Fate of Chemicals 19(2): 498-502
Anderson, R.H.; Ho, S.Y. 1991: The disposition of the conduction tissues in congenitally malformed hearts with reference to their embryological development Journal of Perinatal Medicine 19 Suppl. 1: 201-206
Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Kutter, E.; Austel, V. 1981: Application of the theory of sets to drug design. Development of a new cardiotonic drug AR-L 115 BS Arzneimittel-Forschung 31(1a): 135-141